Kcentra 1,000 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FMEH6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,343
Award facts
- Contract value 100% obligated
- $17,343.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,343.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 1,000 unit vials of Kcentra. This firm fixed-price delivery order, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a regional prime vendor contractor under the broader $30.3 billion PPV-G GEN V acquisition strategy, authorized to supply a comprehensive range of pharmaceutical products to support Department of Defense military healthcare facilities worldwide. The company's performance on this and numerous other delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system. Kcentra, a factor II, VII, IX, and X complex (vitamin K-dependent clotting factors), represents a critical therapeutic product for emergency hemostasis management within military medical operations.
Quick answers
Who was awarded contract SPE2DR26FMEH6?
SPE2DR26FMEH6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FMEH6 worth?
The government has obligated $17,343 on SPE2DR26FMEH6.
Is contract SPE2DR26FMEH6 an order under another contract?
Yes. SPE2DR26FMEH6 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEH6 competed?
The extent of competition for SPE2DR26FMEH6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award